546 related articles for article (PubMed ID: 34289375)
1. Cardiovascular disease in diabetes, beyond glucose.
Eckel RH; Bornfeldt KE; Goldberg IJ
Cell Metab; 2021 Aug; 33(8):1519-1545. PubMed ID: 34289375
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.
Giorgino F; Leonardini A; Laviola L
Ann N Y Acad Sci; 2013 Apr; 1281(1):36-50. PubMed ID: 23387439
[TBL] [Abstract][Full Text] [Related]
3. [Is an intensive glycaemic control beneficial in diabetes type 2?].
Martin S
Dtsch Med Wochenschr; 2011 Sep; 136(39):1940. PubMed ID: 21948602
[No Abstract] [Full Text] [Related]
4. Multifactorial aspects of the treatment of the type II diabetic patient.
Colwell JA
Metabolism; 1997 Dec; 46(12 Suppl 1):1-4. PubMed ID: 9439550
[TBL] [Abstract][Full Text] [Related]
5. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
6. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
Giaccari A; Sorice G; Muscogiuri G
Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):365-77. PubMed ID: 19428228
[TBL] [Abstract][Full Text] [Related]
7. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
9. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
10. Postprandial hyperglycemia as an etiological factor in vascular failure.
Node K; Inoue T
Cardiovasc Diabetol; 2009 Apr; 8():23. PubMed ID: 19402896
[TBL] [Abstract][Full Text] [Related]
11. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
[No Abstract] [Full Text] [Related]
12. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
13. Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation.
Senior PA
Atherosclerosis; 2021 Oct; 335():16-22. PubMed ID: 34520887
[TBL] [Abstract][Full Text] [Related]
14. Diabetes medications and cardiovascular disease: at long last progress.
Lupsa BC; Inzucchi SE
Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
16. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
17. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
18. [Glycemic control and cardiovascular diseases in type 2 diabetes].
Madsbad S
Ugeskr Laeger; 2008 Nov; 170(45):3634. PubMed ID: 18986612
[No Abstract] [Full Text] [Related]
19. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
[TBL] [Abstract][Full Text] [Related]
20. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal T; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2011 Jun; (6):CD008143. PubMed ID: 21678374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
